1. Bánóczy J, Csiba Á. Occurrence of epithelial dysplasia in oral leukoplakia: analysis and follow-up study of 12 cases. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 1976;42(6):766-774.
2. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36(10):575- 580.
3. 高須淳. 口腔病変診断アトラス. 含歯性嚢胞. 1980:98-101.
4. Nagao T, Warnakulasuriya S, Hasegawa S, et al. Elucidating risk factors for oral leukoplakia affecting gingivae in Japanese subjects. Translational Research in Oral Oncology. 2016;1(0).
5. Skach M, Svoboda O, Kutat K. Prispevek k. problému leukoplakie. Acta Univ Carol Ser Med Supp. 1960;10:363-371.
6. Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clinical Cancer Research. 2000;6(5):1702-1710.
7. Jr SS, Gorsky M, Ms FL, Dds. Oral leukoplakia and malignant transformation. A follow‐up study of 257 patients. Cancer. 1984;53(3):563-568.
8. Pindborg J, Jølst O, Renstrup G, Roed-Petersen B. Studies in oral leukoplakia: a preliminary report on the period pervalence of malignant transformation in leukoplakia based on a follow-up study of 248 patients. The Journal of the American Dental Association. 1968;76(4):767-771.
9. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nature reviews Cancer. 2011;11(1):9-22.
10. Wang Z, Feng X, Liu X, et al. Involvement of potential pathways in malignant transformation from oral leukoplakia to oral squamous cell carcinoma revealed by proteomic analysis. BMC genomics. 2009;10(1):383.
11. Isola G, Matarese G, Cordasco G, Rotondo F, Crupi A, Ramaglia L. Anticoagulant therapy in patients undergoing dental interventions: a critical review of the literature and current perspectives. Minerva Stomatol. 2015;64(1):21-46.
12. Nagao T, Warnakulasuriya S, Sakuma H, et al. p53 and ki67 as biomarkers in determining response to chemoprevention for oral leukoplakia. J Oral Pathol Med. 2016.
13. de Vicente JC, Rodrigo JP, Rodriguez-Santamarta T, Lequerica-Fernández P, Allonca E, García-Pedrero JM. Podoplanin expression in oral leukoplakia: tumorigenic role. Oral oncology. 2013;49(6):598-603.
14. Schaaij-Visser TB, Bremmer JF, Braakhuis BJ, et al. Evaluation of cornulin, keratin 4, keratin 13 expression and grade of dysplasia for predicting malignant progression of oral leukoplakia. Oral oncology. 2010;46(2):123-127.
15. Al-Dhohorah T, Mashrah M, Yao Z, Huang J. Aberrant DKK3 expression in the oral leukoplakia and oral submucous fibrosis: a comparative immunohistochemical study. European journal of histochemistry : EJH. 2016;60(2):2629.
16. Rai B, Kaur J, Jacobs R, Singh J. Possible action mechanism for curcumin in pre- cancerous lesions based on serum and salivary markers of oxidative stress. Journal of oral science. 2010;52(2):251-256.
17. Zamora‐Perez A, Ortiz‐García Y, Lazalde‐Ramos B, et al. Increased micronuclei and nuclear abnormalities in buccal mucosa and oxidative damage in saliva from patients with chronic and aggressive periodontal diseases. Journal of periodontal research. 2015;50(1):28-36.
18. Ferlazzo N, Currò M, Zinellu A, et al. Influence of MTHFR genetic background on p16 and MGMT methylation in oral squamous cell cancer. International journal of molecular sciences. 2017;18(4):724.
19. Chaves ALF, Silva AG, Maia FM, et al. Reduced CD8+ T cells infiltration can be associated to a malignant transformation in potentially malignant oral epithelial lesions. Clinical oral investigations. 2019;23(4):1913-1919.
20. Ishii T, Yanagawa T, Yuki K, Kawane T, Yoshida H, Bannai S. Low micromolar levels of hydrogen peroxide and proteasome inhibitors induce the 60-kDa A170 stress protein in murine peritoneal macrophages. Biochemical and biophysical research communications. 1997;232(1):33-37.
21. Ishii T, Yanagawa T, Kawane T, et al. Murine peritoneal macrophages induce a novel 60-kDa protein with structural similarity to a tyrosine kinase p56 lck-associated protein in response to oxidative stress. Biochemical and biophysical research communications. 1996;226(2):456-460.
22. 柳川徹. 外傷歯における生体のストレスと p62 の機能: p62 とストレス応答・オートファジーの観点から. 日本外傷歯学会雑誌. 2015;11(1):1-8.
23. Joung I, Strominger JL, Shin J. Molecular cloning of a phosphotyrosine-independent ligand of the p56lck SH2 domain. Proceedings of the National Academy of Sciences. 1996;93(12):5991-5995.
24. Puls A, Schmidt S, Grawe F, Stabel S. Interaction of protein kinase C ζ with ZIP, a novel protein kinase C-binding protein. Proceedings of the National Academy of Sciences. 1997;94(12):6191-6196.
25. Shin J. P62 and the sequestosome, a novel mechanism for protein metabolism. Archives of pharmacal research. 1998;21(6):629-633.
26. Komatsu M, Waguri S, Koike M, et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell. 2007;131(6):1149-1163.
27. Kitamura H, Torigoe T, Asanuma H, et al. Cytosolic overexpression of p62 sequestosome 1 in neoplastic prostate tissue. Histopathology. 2006;48(2):157-161.
28. Umemura A, He F, Taniguchi K, et al. p62, upregulated during preneoplasia, induces hepatocellular carcinogenesis by maintaining survival of stressed HCC-initiating cells. Cancer cell. 2016.
29. Yu H, Su J, Xu Y, et al. p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins. European Journal of Cancer. 2011;47(10):1585-1594.
30. Mohamed A, Ayman A, Deniece J, et al. P62/Ubiquitin IHC Expression Correlated with Clinicopathologic Parameters and Outcome in Gastrointestinal Carcinomas. Frontiers in oncology. 2015;5:70.
31. Inami Y, Waguri S, Sakamoto A, et al. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. The Journal of cell biology. 2011;193(2):275-284.
32. Rolland P, Madjd Z, Durrant L, Ellis IO, Layfield R, Spendlove I. The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocrine-related cancer. 2007;14(1):73-80.
33. Inui T, Chano T, Takikita-Suzuki M, Nishikawa M, Yamamoto G, Okabe H. Association of p62/SQSTM1 excess and oral carcinogenesis. PloS one. 2013;8(9):e74398.
34. Pankiv S, Clausen TH, Lamark T, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. Journal of biological chemistry. 2007.
35. Ichimura Y, Kumanomidou T, Sou Y-s, et al. Structural basis for sorting mechanism of p62 in selective autophagy. Journal of Biological Chemistry. 2008;283(33):22847-22857.
36. Hu T, Guan T, Gerace L. Molecular and functional characterization of the p62 complex, an assembly of nuclear pore complex glycoproteins. The Journal of Cell Biology. 1996;134(3):589-601.
37. Liu J, Chen F, Lung J, et al. Prognostic significance of p62/SQSTM1 subcellular localization and LC3B in oral squamous cell carcinoma. British journal of cancer. 2014;111(5):944.
38. Lau A, Wang X-J, Zhao F, et al. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Molecular and cellular biology. 2010;30(13):3275-3285.
39. Komatsu M, Kurokawa H, Waguri S, et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nature cell biology. 2010;12(3):213.
40. Ishii T, Itoh K, Takahashi S, et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. Journal of Biological Chemistry. 2000;275(21):16023-16029.
41. 水島昇, 吉森保. オートファジー—生命をささえる細胞の自己分解システム. In: 化学同人; 2012.
42. 村田茂穂, 田中啓二. ユビキチン・プロテアソーム系による タンパク質の品質管理. 神経研究の進歩. 2004;48(1):17-25.
43. 小松雅明. 選択的オートファジー. 臨床検査. 2009;53(12):1543-1549.
44. Mizushima N. Autophagy: process and function. Genes & development. 2007;21(22):2861-2873.
45. Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. Nature reviews Molecular cell biology. 2008;9(12):1004.
46. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic implications. Molecular cancer therapeutics. 2011;10(9):1533-1541.
47. Gunst J, Derese I, Aertgeerts A, et al. Insufficient autophagy contributes to mitochondrial dysfunction, organ failure, and adverse outcome in an animal model of critical illness. Critical care medicine. 2013;41(1):182-194.
48. Liu C, Xu P, Chen D, et al. Roles of autophagy‑related genes Beclin‑1 and LC3 in the development and progression of prostate cancer and benign prostatic hyperplasia. Biomedical reports. 2013;1(6):855-860.
49. Wolfe DM, Lee Jh, Kumar A, Lee S, Orenstein SJ, Nixon RA. Autophagy failure in A lzheimer's disease and the role of defective lysosomal acidification. European Journal of Neuroscience. 2013;37(12):1949-1961.
50. 山田久陽. 基礎細胞生物学. ファルマシア. 2011;47(9):838-838.
51. Kasai H, Nishimura S. Hydroxylation of deoxyguanosine at the C-8 position by ascorbic acid and other reducing agents. Nucleic acids research. 1984;12(4):2137-2145.
52. Dizdaroglu M. Formation of 8-hydroxyguanine moiety in deoxyribonucleic acid on. gamma.-irradiation in aqueous solution. Biochemistry. 1985;24(16):4476-4481.
53. Floyd R, Watson J, Harris J, West M, Wong P. Formation of 8-hydroxydeoxyguanosine, hydroxyl free radical adduct of DNA in granulocytes exposed to the tumor promoter, tetradeconylphorbolacetate. Biochemical and biophysical research communications. 1986;137(2):841-846.
54. Shibutani S, Takeshita M, Grollman AP. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. nature. 1991;349(6308):431.
55. Wood ML, Dizdaroglu M, Gajewski E, Essigmann JM. Mechanistic studies of ionizing radiation and oxidative mutagenesis: genetic effects of a single 8-hydroxyguanine (7- hydro-8-oxoguanine) residue inserted at a unique site in a viral genome. Biochemistry. 1990;29(30):7024-7032.
56. Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb LA. 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G----T and A C substitutions. Journal of Biological Chemistry. 1992;267(1):166-172.
57. 中別府雄作. 核酸の酸化と発癌. 医学のあゆみ. 2005;214(11):949-952.
58. 中別府雄作. 核酸の酸化損傷に起因する神経変性の分子機序―8-オキソグアニンはDNA 修復反応に依存して神経変性を引き起こす. 医学のあゆみ. 2013;247(9):961-968.
59. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137(3):413-431.
60. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer research. 1991;51(23 Part 1):6304-6311.
61. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell. 1989;57(7):1083-1093.
62. Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harbor perspectives in biology. 2009:a001883.
63. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes & cancer. 2011;2(4):466-474.
64. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253(5015):49-53.
65. Brož DK, Attardi LD. In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models. Carcinogenesis. 2010;31(8):1311-1318.
66. Gronostajski RM, Goldberg A, Pardee A. Energy requirement for degradation of tumor- associated protein p53. Molecular and cellular biology. 1984;4(3):442-448.
67. Finlay C, Hinds P, Tan T, Eliyahu D, Oren M, Levine A. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Molecular and cellular biology. 1988;8(2):531-539.
68. Hussain SP, Harris CC. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer research. 1998;58(18):4023-4037.
69. Oren M. p53: the ultimate tumor suppressor gene? The FASEB Journal. 1992;6(13):3169-3176.
70. Sakai E, Tsuchida N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene. 1992;7(5):927-933.
71. JM Braakhuis B, René Leemans C, H. Brakenhoff R. A genetic progression model of oral cancer: current evidence and clinical implications. Journal of oral pathology & medicine. 2004;33(6):317-322.
72. 藤井佳人. 口腔前癌病変および扁平上皮癌における増殖細胞核抗原 (PCNA) と p53 蛋白の発現に関する免疫組織化学的研究. 岩手医科大学歯学雑誌. 1996;21(3):286-299.
73. 西村泰典, 和唐雅博. 口腔癌における p53 の発現および Ki-67 抗原の局在と腫瘍の分化度および浸潤性との関連. 歯科医学. 1994;57(5):325-334.
74. Gusterson B, Anbazhagan R, Warren W, et al. Expression of p53 in premalignant and malignant squamous epithelium. Oncogene. 1991;6(10):1785-1789.
75. Schonk D, Kuijpers H, Van Drunen E, et al. Assignment of the gene (s) involved in the expression of the proliferation-related Ki-67 antigen to human chromosome 10. Human genetics. 1989;83(3):297-299.
76. Fonatsch C, Duchrow M, Rieder H, Schlüter C, Gerdes J. Assignment of the human Ki- 67 gene (MKI67) to 10q25-qter. Genomics. 1991;11(2):476-477.
77. Sasaki K, Murakami T, Kawasaki M, Takahashi M. The cell cycle associated change of the Ki‐67 reactive nuclear antigen expression. Journal of cellular physiology. 1987;133(3):579-584.
78. Shi S-R, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. Journal of Histochemistry & Cytochemistry. 1991;39(6):741-748.
79. Dowsett M, Nielsen TO, A’hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. Journal of the National Cancer Institute. 2011;103(22):1656-1664.
80. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. JNCI: Journal of the National Cancer Institute. 2009;101(10):736-750.
81. Tzanakis N, Peros G, Karakitsos P, et al. Prognostic significance of p53 and Ki67 proteins expression in Greek gastric cancer patients. Acta Chirurgica Belgica. 2009;109(5):606-611.
82. Melling N, Kowitz CM, Simon R, et al. High Ki67 expression is an independent good prognostic marker in colorectal cancer. Journal of clinical pathology. 2016;69(3):209-214.
83. Al-Saleh W, Delvenne P, Greimers R, Fridman V, Doyen J, Boniver J. Assessment of Ki- 67 antigen immunostaining in squamous intraepithelial lesions of the uterine cervix: correlation with the histologic grade and human papillomavirus type. American journal of clinical pathology. 1995;104(2):154-160.
84. Ma X, Wu Y, Zhang T, et al. Ki67 proliferation index as a histopathological predictive and prognostic parameter of oral mucosal melanoma in patients without distant metastases. Journal of Cancer. 2017;8(18):3828.
85. Valente G, Orecchia R, Gandolfo S, et al. Can Ki67 immunostaining predict response to radiotherapy in oral squamous cell carcinoma? Journal of clinical pathology. 1994;47(2):109-112.
86. 小宮山和正. 舌癌の増殖能に関する免疫組織化学的研究 Ki‐67 抗原発現と組織学的悪性度との関連性について. 日本口腔外科学会雑誌. 1995;41(3):179-190.
87. 川崎五郎, 柳本惣市, 陶山一隆, 水野明夫. 舌扁平上皮癌症例における Ki-67 抗原の発現と組織学的悪性度評価との関連について. 日本口腔科学会雑誌. 1999;48(2):116-120.
88. Terabe T, Uchida F, Nagai H, et al. Expression of autophagy-related markers at the surgical margin of oral squamous cell carcinoma correlates with poor prognosis and tumor recurrence. Human pathology. 2018;73:156-163.
89. Barnes L, Eveson J, Reichart P, Sidransky D. World Health Organization classifications tumours. Pathology and genetics of head and neck tumours. Lyon: IARC. 2005.
90. Nagao T, Warnakulasuriya S, Sakuma H, et al. p53 and ki67 as biomarkers in determining response to chemoprevention for oral leukoplakia. Journal of Oral Pathology & Medicine. 2017;46(5):346-352.
91. Choi J, Jung W, Koo JS. Expression of autophagy‐related markers beclin‐1, light chain 3A, light chain 3B and p62 according to the molecular subtype of breast cancer. Histopathology. 2013;62(2):275-286.
92. Petti S. Lifestyle risk factors for oral cancer. Oral oncology. 2009;45(4-5):340-350.
93. Meisel P, Holtfreter B, Biffar R, Suemnig W, Kocher T. Association of periodontitis with the risk of oral leukoplakia. Oral oncology. 2012;48(9):859-863.
94. Srivastava KC, Austin RD, Shrivastava D, Pranavadhyani G. Oxidant-antioxidant status in tissue samples of oral leukoplakia. Dental research journal. 2014;11(2).
95. Kiffin R, Bandyopadhyay U, Cuervo AM. Oxidative stress and autophagy. Antioxidants & redox signaling. 2006;8(1-2):152-162.
96. Lee J-M, Johnson JA. An important role of Nrf2-ARE pathway in the cellular defense mechanism. BMB Reports. 2004;37(2):139-143.
97. Jain A, Lamark T, Sjottem E, et al. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element- driven gene transcription. Journal of Biological Chemistry. 2010:jbc. M110. 118976.
98. Smith J, Rattay T, McConkey C, Helliwell T, Mehanna H. Biomarkers in dysplasia of the oral cavity: a systematic review. Oral oncology. 2009;45(8):647-653.
99. Mishra R. Biomarkers of oral premalignant epithelial lesions for clinical application. Oral oncology. 2012;48(7):578-584.
100. Cervigne NK, Reis PP, Machado J, et al. Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Human molecular genetics. 2009;18(24):4818-4829.
101. Dionne KR, Warnakulasuriya S, Zain RB, Cheong SC. Potentially malignant disorders of the oral cavity: current practice and future directions in the clinic and laboratory. International journal of cancer. 2015;136(3):503-515.
102. Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nature reviews Cancer. 2005;5(2):127-135.
103. Hunter KD, Thurlow JK, Fleming J, et al. Divergent routes to oral cancer. Cancer research. 2006;66(15):7405-7413.
104. Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000;6(5):1702-1710.
105. Beenken SW, Huang P, Sellers M, et al. Retinoid modulation of biomarkers in oral leukoplakia/dysplasia. Journal of cellular biochemistry Supplement. 1994;19:270-277.
106. Mutirangura A, Supiyaphun P, Trirekapan S, et al. Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. Cancer research. 1996;56(15):3530-3533.
107. Matta A, Tripathi SC, DeSouza LV, et al. Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma. International journal of cancer. 2009;125(6):1398-1406.
108. Mathew R, Karp CM, Beaudoin B, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell. 2009;137(6):1062-1075.
109. Lévy J, Cacheux W, Bara MA, et al. Intestinal inhibition of Atg7 prevents tumour initiation through a microbiome-influenced immune response and suppresses tumour growth. Nature cell biology. 2015.
110. Twitty CG, Jensen SM, Hu H-M, Fox BA. Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism. Clinical Cancer Research. 2011;17(20):6467-6481.
111. Puissant A, Robert G, Fenouille N, et al. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer research. 2010;70(3):1042-1052.
112. Bitto A, Lerner CA, Nacarelli T, Crowe E, Torres C, Sell C. P62/SQSTM1 at the interface of aging, autophagy, and disease. Age. 2014;36(3):9626.
113. Liu S-C, Sauter ER, Clapper ML, et al. Markers of cell proliferation in normal epithelia and dysplastic leukoplakias of the oral cavity. Cancer Epidemiology and Prevention Biomarkers. 1998;7(7):597-603.
114. Yan S-K, Wei B-J, Lin Z-Y, Yang Y, Zhou Z-T, Zhang W-D. A metabonomic approach to the diagnosis of oral squamous cell carcinoma, oral lichen planus and oral leukoplakia. Oral oncology. 2008;44(5):477-483.
115. Ruan H, Xu J, Wang L, et al. The prognostic value of p62 in solid tumor patients: a meta-analysis. Oncotarget. 2018;9(3):4258.